Treatment of autoimmune hemolytic anemia with erythropoietin: A case report
Main Article Content
Abstract
In this article, we describe the case of a fifty-year-old patient with autoimmune hemolytic anemia (AIHA) with constitutional symptoms, jaundice, unquantified fever and progressive dyspnea. The patient had history of smoking and Hepatitis A and following a physical exam she was found in a regular condition, icteric but with no other further signs. Her laboratory tests revealed hemolytic anemia with a hemoglobin of 8.5 g/dL, an increase of total and indirect bilirubin, an elevated ferritin, a decreased transferrin and haptoglobin and a positive result for direct Coomb’s test. Considering this, an immune profile was ordered finding a negative result of ANAs and ENAs and a decrease of complement C3 and C4. The patient was diagnosed with AIHA and as an initial step a corticosteroid treatment was administrated however the patient showed no clinical nor chemical improvement. At her third day of hospitalization, she was unstable hemodynamically requiring transfer to Intensive Care Unit (ICU) to optimize management. After 24 hours on ICU, due to persistence of deterioration of the patient, it was decided to manage with erythropoietin (EPO). In the following days, the patient showed a rise in her hemoglobin and an overall improvement made possible the transfer to hospitalization service. The AIHA is an uncommon disease and is not the first option that comes to mind with these symptoms, currently there are not controlled studies to the treatment due to its complexity and the heterogeneity of the results. We strongly support the use of EPO in refractory cases of this pathology.
Article Details
Copyright (c) 2019 Ovalle JP, et al.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
Permission to read and download | ✓ |
Permission to display in a repository | ✓ |
Permission to translate | ✓ |
Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Anemia, Hemolytic, Autoimmune. MeSH. 2019. PubMed: https://www.ncbi.nlm.nih.gov/mesh/68000744
Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematol Am Soc Hematol Educ Program. 2016; 2016: 690–697. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142448/
Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014; 13: 560–564. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24418298
Liebman HA, Weitz IC. Autoimmune Hemolytic Anemia. Med Clin North Am. 2017; 101: 351–359. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28189175
Jaime-Pérez JC, Aguilar-Calderón P, Salazar-Cavazos L, Gómez-De León A, Gómez-Almaguer D. Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico. Blood Res. 2019; 54: 131–136. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31309092
Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016; 2016: CD007745–CD007745. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26778150
Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017; 129: 2971–2979. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28360039
Salama A. Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review. Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatologie. 2015; 42: 294–301. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678315/
Erythropoietin. MeSH. 2019. PubMed: https://www.ncbi.nlm.nih.gov/mesh/68004921
Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012; 26: 107–115. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22330255
Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015; 29: 455–471. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26043385
Zeerleder S. Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge. Neth J Med. 2011; 69: 177–184. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21527804
Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019; 3: 1897–1906. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31235526
Naik R. Warm autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015; 29: 445–453. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26043384
Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med. 2019; 381: 647–654. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31412178
Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124: 2930–2936. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25232059
Arbach O, Funck R, Seibt F, Salama A. Erythropoietin May Improve Anemia in Patients with Autoimmune Hemolytic Anemia Associated with Reticulocytopenia. Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatologie. 2012; 39: 221–223. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22851939
Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 2012; 14: 238–246. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278592/
Haley K. Congenital Hemolytic Anemia. Med Clin North Am. 2017; 101: 361–374. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28189176
Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study. Pediatr Nephrol Berl Ger. 2015; 30: 339–344. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25138373